Sleep Disorders in Long COVID: The Autonomic Connection

Sleep disruption affects an estimated 60–80% of Long COVID patients and is consistently rated among the most debilitating symptoms. Unlike typical insomnia — which is primarily driven by psychological factors — sleep disorders in Long COVID appear to have distinct neurological, autonomic, and inflammatory underpinnings. Understanding these mechanisms is essential for choosing treatments that actually work, rather than those designed for conventional insomnia.

Types of Sleep Disruption in Long COVID

Long COVID patients report a wide range of sleep problems, often occurring simultaneously:

• Difficulty falling asleep (sleep onset insomnia)
• Frequent nighttime awakening (sleep maintenance insomnia)
• Non-restorative sleep — sleeping for adequate hours but waking exhausted
• Vivid, disturbing dreams or nightmares
• Hypersomnia — excessive daytime sleepiness despite adequate nighttime sleep
• Circadian rhythm disruption — shifted sleep-wake cycles
• Sleep apnea — new-onset or worsening obstructive or central sleep apnea

The Autonomic Connection

The autonomic nervous system plays a central role in regulating sleep architecture. The transition from wakefulness to sleep involves a shift from sympathetic (fight-or-flight) to parasympathetic (rest-and-digest) dominance. In Long COVID patients with dysautonomia, this transition is impaired — the sympathetic nervous system remains hyperactivated even at rest, making it difficult to initiate and maintain sleep.

Heart rate variability (HRV) studies in Long COVID patients confirm this pattern: reduced HRV (indicating sympathetic dominance) is associated with worse sleep quality, more frequent nighttime awakening, and greater fatigue the following day. This creates a vicious cycle — poor sleep worsens autonomic dysfunction, which further disrupts sleep.

Orthostatic intolerance also directly disrupts sleep. Many Long COVID patients experience nocturnal tachycardia, palpitations, and sweating — symptoms of sympathetic hyperactivation — that awaken them repeatedly during the night. These nocturnal symptoms are often the most distressing aspect of sleep disruption for POTS patients.

Neuroinflammation and Sleep Architecture

Neuroinflammation — now well-documented in Long COVID — disrupts sleep architecture through multiple pathways. Inflammatory cytokines (IL-1β, TNF-α, IL-6) promote slow-wave sleep (deep sleep) in the short term but disrupt REM sleep and cause fragmented sleep architecture with chronic elevation.

Microglial activation in the hypothalamus and brainstem — regions that regulate circadian rhythms and sleep-wake transitions — may be a key driver of the non-restorative sleep and hypersomnia seen in Long COVID. This is mechanistically similar to the sleep disruption seen in other neuroinflammatory conditions, including multiple sclerosis and post-viral fatigue syndromes.

Circadian Rhythm Disruption

Several Long COVID patients report a shifted circadian rhythm — a tendency to fall asleep very late (2–4 AM) and wake late, or a complete reversal of the sleep-wake cycle. This may reflect disruption of the suprachiasmatic nucleus (SCN) — the brain's master clock — by neuroinflammation or autonomic dysfunction.

Treatment Approaches

Treatment of sleep disorders in Long COVID requires addressing the underlying mechanisms, not just the symptoms.

Addressing autonomic dysfunction first. For patients with POTS or orthostatic intolerance, treating the underlying dysautonomia often significantly improves sleep. Salt and fluid loading, compression garments, beta-blockers (particularly propranolol or metoprolol), and ivabradine can reduce nocturnal tachycardia and sympathetic hyperactivation.

Low-dose naltrexone. LDN has shown benefit for sleep in ME/CFS and fibromyalgia patients, likely through its anti-neuroinflammatory effects. Some Long COVID patients report improved sleep depth and reduced nighttime awakening with LDN.

Melatonin. Low-dose melatonin (0.5–1 mg, 1–2 hours before target sleep time) can help reset circadian rhythms. Higher doses (5–10 mg) are commonly used but may cause morning grogginess and are not necessarily more effective for circadian resetting.

Sleep hygiene adapted for Long COVID. Standard sleep hygiene recommendations require modification for Long COVID patients. Strict sleep restriction therapy (a standard CBT-I technique) can trigger post-exertional malaise and should be avoided. Instead, a consistent but flexible sleep schedule, cool room temperature, and avoidance of screens 1–2 hours before bed are reasonable starting points.

Avoiding antihistamines for sleep. Diphenhydramine (Benadryl) and doxylamine are commonly used OTC sleep aids but are problematic for Long COVID patients — they have significant anticholinergic effects that can worsen cognitive symptoms, and they disrupt sleep architecture.

Low-dose tricyclics or trazodone. Low-dose amitriptyline (5–25 mg) or trazodone (25–100 mg) can improve sleep depth and reduce nighttime awakening in Long COVID patients, with the added benefit of addressing pain and anxiety. These should be used cautiously in patients with POTS, as they can worsen orthostatic hypotension.

Key Takeaways

Sleep disorders in Long COVID are not simply psychological insomnia — they reflect genuine neurological, autonomic, and inflammatory disruption. Effective treatment requires identifying the primary drivers in each patient (autonomic hyperactivation, neuroinflammation, circadian disruption, or sleep apnea) and targeting those mechanisms directly, rather than relying on sedative medications that mask symptoms without addressing root causes.

This article is for informational purposes only and does not constitute medical advice.